First Patient Enrolled in OncoQuest's Phase 1/2 Study Combining Oregovomab with Hiltonol® in Recurrent Ovarian Cancer
- Category: Antibodies
- Published on Wednesday, 26 July 2017 18:46
- Hits: 931
Third Ongoing Study Examining Oregovomab in Combination with Other Drugs in Ovarian Cancer
EDMONTON, Canada I July 26, 2017 I OncoQuest Inc. ("OncoQuest"), a biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, today announced the enrollment of the first patient in a Company-sponsored Phase 1/2 clinical study to evaluate the use of oregovomab in combination with Hiltonol®, an experimental TLR3 agonist acting as an immune adjuvant, in ovarian cancer patients in the recurrent setting. This clinical trial is being conducted at Florida Hospital Cancer Institute in Orlando, Florida with Dr. Robert Holloway as Principal Investigator and at Virginia Commonwealth University's Massey Cancer Center in Richmond, Virginia, with Dr. William McGuire as the Principal Investigator. The clinical trial is managed and monitored by Veristat, a full service Clinical Research Organization (CRO) in Southborough, Massachusetts.
This is the second Phase 1/2 study evaluating oregovomab in combination with other drugs in the recurrent ovarian cancer setting. In the first trial, which was launched in May 2017 and has accrued 6 patients, oregovomab is being used in combination with nivolumab, a checkpoint inhibitor.
In frontline ovarian cancer, OncoQuest recently presented positive interim results from its randomized, controlled multi-center Phase 2 clinical trial with oregovomab in combination with carboplatin and paclitaxel at ASCO, 2017.
"Hiltonol® is an investigational TLR3 agonist that has been found to stimulate both cellular and humoral immune response, and is being tested as an immune adjuvant in a number of oncology studies," said Dr. Madiyalakan, CEO of OncoQuest. "We will evaluate the outcome from this study and our other study using a checkpoint inhibitor combination to identify how best to utilize oregovomab in this important clinical setting" continued Dr. Madiyalakan.